半乳糖凝集素-3作为失代偿性心力衰竭患者急性肾损伤风险的生物标志物。
Galectina-3 as a biomarker of acute kidney injury risk in patients with decompensated heart failure.
作者信息
Sanchez-Serna J, Martinez-Villanueva M, Hernández-Vicente Á, Asensio-Lopez M C, Noguera J A, Pascual-Figal D A
机构信息
Servicio de Cardiología, Hospital Universitario Virgen de la Arrixaca, Murcia, España.
Servicio de Bioquímica, Hospital Universitario Virgen de la Arrixaca, Murcia, España.
出版信息
Rev Clin Esp (Barc). 2019 Aug-Sep;219(6):315-319. doi: 10.1016/j.rce.2018.10.004. Epub 2019 Feb 6.
INTRODUCTION
In decompensated heart failure (HF), both acute kidney injury (AKI) and high Galectina-3 (Gal-3) levels have been associated with poorer outcomes. Plasma Gal-3 levels are affected by renal function; however, the potential role of Gal-3 as a predictor of AKI has not been established.
METHODS
We measured Gal-3 concentrations at admission for 175 patients hospitalised for HF and recorded the onset of AKI according to the Risk, Injury, Failure, Loss and End-stage kidney disease (RIFLE) analytical criteria.
RESULTS
During hospitalisation, 44 patients (25.1%) developed AKI, although only 14 (8%) corresponded to more advanced stages. These 14 patients had significantly higher Gal-3 levels at admission, which remained a predictor of AKI after the multivariate adjustment by other predictors and by baseline renal function.
CONCLUSIONS
High Gal-3 levels at admission are associated with a higher risk of AKI during hospitalisation for decompensated HF.
引言
在失代偿性心力衰竭（HF）中，急性肾损伤（AKI）和高半乳糖凝集素-3（Gal-3）水平均与较差的预后相关。血浆Gal-3水平受肾功能影响；然而，Gal-3作为AKI预测指标的潜在作用尚未确立。
方法
我们对175例因HF住院的患者入院时的Gal-3浓度进行了测量，并根据风险、损伤、衰竭、丧失和终末期肾病（RIFLE）分析标准记录了AKI的发生情况。
结果
住院期间，44例患者（25.1%）发生了AKI，尽管只有14例（8%）处于更晚期阶段。这14例患者入院时的Gal-3水平显著更高，在经其他预测指标和基线肾功能进行多变量调整后，Gal-3仍然是AKI的一个预测指标。
结论
入院时高Gal-3水平与失代偿性HF住院期间发生AKI的较高风险相关。
Zotero 插件